MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025

MaaT Pharma (MAAT) announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for Xervyteg® (MaaT013) for acute graft-versus-host disease, with potential approval and commercialization in Europe expected in H2 2026. Positive Phase 3 ARES study results showed a 62% gastrointestinal overall response rate at Day 28. The company is shifting focus to European registration activities, delaying the Phase 3 trial launch in the U.S. to 2026, while continuing discussions with the FDA.

Analysis

MaaT Pharma has achieved a significant regulatory milestone with the submission of its Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for Xervyteg® (MaaT013) in acute graft-versus-host-disease (aGvHD), a development underpinned by positive pivotal Phase 3 ARES study data demonstrating a 62% gastrointestinal overall response rate at Day 28. This submission positions Xervyteg® for potential EMA approval and subsequent commercialization in Europe by the second half of 2026, potentially establishing it as the first microbiota therapeutic approved by the EMA, the premier one in hemato-oncology worldwide, and the first approved therapy for third-line GI-aGvHD. The company's strategic prioritization of European registration activities, which includes advancing discussions for commercialization partnerships, has resulted in a revised timeline for its U.S. Phase 3 trial initiation to 2026, while U.S. early access programs for Xervyteg® continue. Beyond its lead asset, MaaT Pharma's pipeline demonstrates encouraging progress: MaaT033 has received favorable safety assessments in its Phase 2b PHOEBUS trial for allogenic hematopoietic stem cell transplant, with last patient enrollment anticipated by mid-2026, and proof-of-concept trials for both Xervyteg® and MaaT033 in immuno-oncology are advancing, notably with data from the PICASSO trial (Xervyteg® in metastatic melanoma) expected in H2 2025. Additionally, compelling preclinical data for the next-generation candidate MaaT034, which showed an 83.7% tumor growth reduction in combination with anti-PD-1 therapy, underscores the potential of its MET-C platform. Positive Phase 1b results for MaaT033 in Amyotrophic Lateral Sclerosis, for which a partner is now being sought, also indicate broader therapeutic applicability, even as oncology remains the primary strategic focus.

Key Decisions for Investors

• Investors should closely monitor the EMA review process for Xervyteg®, as potential European approval and commercialization in H2 2026 represent a key value inflection point, and contemporaneously evaluate the terms of any forthcoming European commercialization partnerships.
• The revised 2026 timeline for the Xervyteg® U.S. Phase 3 trial warrants attention; progress in FDA discussions and continued positive data from the U.S. Early Access Program will be critical factors for assessing future U.S. market access and overall valuation.
• Upcoming data readouts, including final 12-month overall survival data from the ARES study for Xervyteg® expected by end of 2025 and results from the PICASSO trial in H2 2025, are significant catalysts that could further de-risk MaaT Pharma's pipeline and validate its Microbiome Ecosystem Therapies™ platform.
• Consider the company's capital allocation strategy between European commercialization efforts for Xervyteg®, the advancement of its U.S. regulatory pathway, and its broader pipeline development, including partnering efforts for MaaT033 in ALS, as these will collectively shape long-term growth prospects.